For US Healthcare Professionals
Prescribing Information for All Merck Products

Request Samples
NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) delivers 0.120 mg/0.015 mg per day
(Please read the Boxed Warning about serious cardiovascular events, especially in women who smoke, in the Prescribing Information.)


Request Samples


MDs, DOs, and other licencsed practioners (depending on state-level requirements) may request samples through MerckProductServices.

Sign In Register Now! 
You can sign in to MerckServices® using your MerckMedicus™ or MerckSource® user name and password.
User name:
Password:
Forgot your user name or password?
 
 Remember me
To request samples, you must sign in. You will then be taken to a list of samples that you may request. When you finalize your requests, you will need to print out a Sample Request Form. This form must be signed, dated, and returned to Merck via fax or mail using the fax number or address specified on the form within the time frame specified. Once the Sample Request Form is validated, most sample requests are shipped within 3-5 business days.

To request complimentary samples, you must sign in. You will then be shown a list of the different complimentary sample formulations for that product that you may request. When you finalize your requests, you will need to print out a Sample Request Form. This form must then be signed, dated, and returned to Merck via fax or mail using the fax number or address specified on the form. You should receive the samples requested via UPS delivery within 14 business days of Merck receiving the completed form.

IMPORTANT PRODUCT INFORMATION


NuvaRing is indicated for the prevention of pregnancy in women.

SELECTED SAFETY INFORMATION

Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination hormonal contraceptives, including NuvaRing should be strongly advised not to smoke.

• The use of combination oral contraceptives is associated with increased risks of several serious side effects, including stroke or heart attack. NuvaRing is not for women with a history of these conditions. Combination oral contraceptives are also associated with increased risk of thromboembolic diseases. Some studies suggest that this risk is increased by combination oral contraceptives containing desogestrel; additional studies do not support this finding. It is unknown whether NuvaRing has a different risk of venous thromboembolism (VTE) than second-generation oral contraceptives.

• NuvaRing is not for women with certain cancers or those who may be pregnant.

• NuvaRing does not protect against HIV infection and other sexually transmitted diseases.

• The most common adverse events reported by 5% to 14% of women using NuvaRing in clinical trials (n=2501) were vaginitis, headache, upper respiratory tract infection, vaginal secretion, sinusitis, weight gain, and nausea.

Please click here for full Prescribing Information including Boxed Warning.

All product names listed on this site are registered trademarks owned by or licensed to a subsidiary of Merck & Co., Inc.
MerckProductServices, MerckServices, MerckSource, Merck OnCall, MerckMedicus, and MerckEngage are trademarks or registered trademarks of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.